New migraine help for people with MS — what works now

Credibility

Interest

Share:2 min read

Key Takeaway

Drugs that block the CGRP migraine pathway helped many people with MS cut their monthly headaches roughly in half without making MS worse.

What They Found

Researchers looked back at 54 adults with multiple sclerosis (MS) who also had migraine and started medicines that target the CGRP pathway (a chemical involved in migraine). On average, people had about 20 headache days per month before treatment and this dropped to about 11 days per month after treatment, and they used fewer pain pills. About 54% of patients had at least a 50% drop in monthly headache days, which the study calls a good response. MS activity—measured by relapses (new attacks), disability scores, and MRI scans—stayed stable, meaning the migraine drugs did not seem to make MS worse. People with more headache days at the start tended to improve more, while those who had lived with MS longer were less likely to have a strong benefit.

Who Should Care and Why

People with MS who also get frequent migraines should care because these results suggest a new option that can cut headache days and reduce pain pill use, which may make daily life easier. Caregivers may notice loved ones have fewer bad days and need less rescue medicine, helping with planning and support. Neurologists and MS clinic teams should know these medicines appear safe in people whose MS treatment is stable, so they can consider them alongside existing MS medicines. Think of it like adding a targeted tool to your toolbox: it focuses on the migraine pathway without disturbing MS control. Those with very long-standing MS or fewer headache days to start may not get as big a benefit, so individual discussions with a doctor are important.

Important Considerations

This study looked back at past patient records (retrospective) from 54 people, which can miss details and is not as strong as a randomized trial. All patients were already on stable MS treatments, so the results may not apply to people changing MS therapy or with different health situations. While no major safety problems appeared, the number of patients was small, so rare side effects or longer-term issues might not have shown up yet.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates Clinical Trials Specific Symptoms

Article Topics:

CGRPDisease-modifying therapiesMigraineMultiple sclerosis

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like The journal of headache and pain often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News